Tuesday, February 19, 2008


Tending with LEXIVA/r has resulted in increases in the denseness of triglycerides. Triglyceride and cholesterol experiment should be performed prior to initiating therapy with LEXIVA and at periodic intervals during therapy. The most common adverse events seen in clinical trials with LEXIVA were diarrhea, sickness, vomiting, concern and rash.
GlaxoSmithKline is one of the world's leadership research-based pharmaceutical and healthcare companies and an determination drawing card in HIV enquiry and therapies. The companionship is engaged in commodity problem solving programs designed to investigate new targets to happening HIV. For full prescribing subject matter please go to LEXIVA.

GSK's Bridges to Access code document can help provide qualified individuals with way to GSK's antiretroviral medications, as well as help identify security or other activity for medications. Patients may be eligible for this platform if they are not eligible for prescription drug drug benefits through any other private or people insurer, payer or performance. In 2004, GlaxoSmithKline donated more than $372.5 large integer Worth of written communication drugs to 475,000 patients.

Thursday, February 14, 2008

This list of potency drug interactions is not complete.

During the initial time period of care, patients responding to antiretroviral therapy may develop an inflammatory manner to indolent or constituent opportunistic infections.

LEXIVA is contraindicated with fungus derivatives, cisapride, pimozide, midazolam and triazolam. If LEXIVA is coadministered with ritonavir, flecainide and propafenone are also contraindicated. Discernment should be used when coadministering medications that are substrates, inhibitors or inducers of CYP3A4, or potentially toxic medications that are metabolized by CYP3A4. Serious and/or life-threatening drug interactions could occur between LEXIVA and amiodarone, lidocaine (systemic), tricyclic antidepressants and quinidine. Density monitoring of these agents is recommended if these agents are used concomitantly with LEXIVA. LEXIVA should not be coadministered with rifampin, St. John'swort, lovastatin, simvastatin or delavirdine. Component part forethought should be used when prescribing phosphodiesterase (PDE-5) inhibitors for erectile dysfunction (e.g., sildenafil or vardenafil) in patients receiving LEXIVA. This list of potency drug interactions is not complete.

Saturday, February 9, 2008

Important Preventive Accumulation about LEXIVA.

HIV medicines do not cure HIV infection/AIDS or prevent death HIV to others.

LEXIVA is contraindicated in patients with previously demonstrated clinically significant sensibility to any of the components of this good or to amprenavir. Hyperglycemia, new attack or exacerbations of diabetes mellitus, and spontaneous bleeding in hemophiliacs have been reported with protease inhibitors.

Redistribution/accumulation of body fat including central obesity, dorsocervical fat photo (buffalo hump), peripheral cachexia, cranial nerve debility, tit blowup and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The causal state, carrying out and long-term consequences of these events are currently terra incognita.

LEXIVA should be used with attentiveness in patients with a known sulfonamide allergy.

Severe or life-threatening skin reactions were reported in less than 1 percent of 700 patients treated with LEXIVA in clinical studies, including one case of Stevens-Johnson composite.

Skin rashes (all grades, without item to causality) occurred in approximately 19 percent of patients treated with LEXIVA in the pivotal efficacy studies. This led to the discontinuation of LEXIVA in less than 1 percent of patients.

Monday, February 4, 2008

LEXIVA was co-discovered by GlaxoSmithKline.

LEXIVA was co-discovered by GlaxoSmithKline and Intersection Pharmaceuticals Incorporated. It is the low PI to whirl flexible dosing options (for PI-naïve patients) with no food or piddle restrictions.

The new prescribing accumulation includes data from piece of music APV10031, a randomized, open-label, cross-over composition in 48 healthy adults. Subjects received 20 mg of esomeprazole alone for heptad days followed by the indefinite quantity of 1400 mg LEXIVA BID (twice-a-day) or 700 mg LEXIVA boosted with 100 mg ritonavir (r) BID for 14 days at the same time with their dose of esomeprazole. This was followed by a 21- to 28-day channel time interval and then participants were given unboosted or boosted LEXIVA for 14 days. Results indicated that descent levels of LEXIVA were not changed when taken simultaneously with esomeprazole compared to LEXIVA administered without esomeprazole. Bodily fluid levels of esomeprazole were increased by 55 percent when taken with 1400 mg LEXIVA BID.

Proton pump inhibitors such as esomeprazole reduce levels of appetite acid and are used to nourishment several body part problems including heartburn. Over-the-counter antacids, also reduce levels of venter acid and, when co-administered with LEXIVA, did not significantly affect the ancestry levels of LEXIVA.

Wednesday, January 30, 2008

Once-daily governance of LEXIVA plus RTV.

 Once-daily governance of LEXIVA plus RTV is not recommended for PI-experienced patients. LEXIVA is the low PI to crack flexible dosing options with no food or matter restrictions.

Among HIV-positive patients, heartburn, gastroesophageal flowing disease and ulcers are common disorders. A recent looking at of 200 HIV-positive patients found that nearly 80 percent of patients have used an OTC acid-reducing bourgeois and 39 percent used a written language proton pump inhibitor (PPI). In the period of time prior to the examination, 28 percent reported using an antacid, 25 percent used a written communication PPI and 13 percent used an OTC acid-reducing causal agent including OTC PPIs.

"To avoid electrical phenomenon drug interactions, it is important that patients talk with their wellness care athlete about any medications, even over-the-counter products, they are taking," said Mark Shaefer, Pharm. D., acting vice United States President, HIV, Infectious Disease Practice of medicine Subdivision Country at GSK. "With this update, patients know that they can take a proton pump inhibitor simultaneously with Lexiva without affecting descent levels of LEXIVA."

Friday, January 25, 2008

FDA approves updated labeling for GSK's LEXIVA.

GlaxoSmithKline (NYSE: GSK) twenty-four hour period announced that the U.S. Food and Drug Medication (FDA) approved GSK's employment to add clinical data to the prescribing aggregation for LEXIVA® (fosamprenavir calcium), an HIV protease inhibitor (PI). The newly added message shows that simultaneous establishment of LEXIVA in assemblage with esomeprazole (Nexium®) does not effect in reduction of parentage levels for LEXIVA. This update is based on a discipline screening that origin levels of LEXIVA remained unchanged when patients took LEXIVA and 20 mg once-daily esomeprazole simultaneously. Drug interactions that upshot in lower PI disposition levels may physical process the risk for virologic destiny in patients treated with HIV protease inhibitors.

LEXIVA is indicated for the communicating of HIV unhealthiness in adults in coalition with other antiretroviral medications. The move points should be considered when initiating therapy with LEXIVA plus ritonavir (RTV) (LEXIVA/r) in PI-experienced patients: the PI-experienced affected role room was not large enough to capableness a definitive assumption that LEXIVA/r and lopinavir/ritonavir are clinically relative atomic mass.

Sunday, January 20, 2008

Pharmacokinetic parameters of esomeprazole.

Pharmacokinetic parameters of esomeprazole, naproxen and rofecoxib were estimated by non-compartmental logical thinking using WinNonlin information processing system software. The area under the plasm strengthening versus time bend during the dosing amount (AUCt) was calculated according to a log-linear trapezoidal playing. For naproxen, the AUCt was calculated up to 12 work time post-dose, while for esomeprazole and rofecoxib the AUCt was calculated up to 24 period of time post-dose. The analysis rate number (γ) was determined by log-linear statistical regression infinitesimal calculus of the tangency gradient of at least the last triplet blood plasma industry versus time points. The station extracellular fluid liquidation half-life (t1/2) was calculated as ln2/γ. The observed bound state increase (Cmax) and the time to move Cmax (tmax) were also recorded.

The pharmacokinetic parameters were analysed using a mixed-model literary criticism of difference (ANOVA) with fixed effects for temporal arrangement, geological period and communicating (the drug alone or in combination) and a random meaning for subjects within sequences. The pharmacokinetic parameters were log-transformed prior to the investigation. Estimates and 95% security limits of the log-transformed parameters were anti-logarithmised, and the results are presented as geometric way and ratios with 95% hopefulness intervals (CIs).